Connacht Asset Management’s Inhibrx, Inc. Common Stock INBX Stock Holding History

Connacht Asset Management’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-9,173	Closed	-$238K	–	104
2023 Q2	$238K	Sell	9,173 -2,260	-20%	-$52.8K	0.33%	84
2023 Q1	$216K	Sell	11,433 -710	-6%	-$16.5K	0.09%	129
2022 Q4	$299K	Sell	12,143 -809	-6%	-$23.8K	0.14%	101
2022 Q3	$232K	Sell	12,952 -1,555	-11%	-$28K	0.16%	110
2022 Q2	$165K	Buy	14,507 +2,146	+17%	+$31.6K	0.07%	146
2022 Q1	$275K	Buy	12,361 +5,266	+74%	+$134K	0.14%	111
2021 Q4	$310K	Buy	+7,095	New	+$284K	0.3%	91

Other funds holding INBX

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Connacht Asset Management's INBX Position: Q3 2023 in Review

Connacht Asset Management sold out of Inhibrx, Inc. Common Stock (INBX) in Q3 2023, closing a stake of 9,173 shares — an estimated $238K sold.

Connacht Asset Management first reported a position in INBX in Q4 2021 and held it in 7 quarters. The position peaked at $310K in Q4 2021. 111 funds tracked by Wall St. Rank hold INBX as of Q3 2023.

Connacht Asset Management reported no remaining Inhibrx, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Connacht Asset Management sold 9,173 Inhibrx, Inc. Common Stock shares in Q3 2023, an estimated $238K.
Connacht Asset Management first reported a position in Inhibrx, Inc. Common Stock in Q4 2021 and held it in 7 quarters.
Connacht Asset Management's Inhibrx, Inc. Common Stock position peaked at $310K in Q4 2021.
111 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q3 2023.

Based on Connacht Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.